China Authorizes Novel CAR-T Therapy for Solid Cancers

Chinese regulators have approved satri-cel, marking the first global CAR-T cell therapy specifically for solid tumors. This treatment targets advanced gastric and gastroesophageal junction adenocarcinoma in patients who have exhausted other options. Clinical trials published in The Lancet indicated both significant effectiveness and a favorable safety profile for the new therapy.